NEX-1 / NEX-2
Rett Syndrome
Pre-clinical / Phase 1Active
Key Facts
About Nexien BioPharma
Nexien BioPharma is a private, pre-revenue biotech leveraging cannabinoid science to address significant unmet medical needs in neurology and rare diseases. The company employs a pharmaceutical development approach to cannabinoids, aiming to overcome the limitations of traditional cannabis-based products through rigorous chemistry, manufacturing, and controls (CMC) and clinical validation. Its pipeline consists of early-stage programs targeting conditions like Rett Syndrome and Dravet Syndrome, positioning it in a high-growth but complex regulatory and competitive landscape. Success hinges on clinical execution, intellectual property strength, and navigating the evolving regulatory framework for cannabinoid pharmaceuticals.
View full company profileTherapeutic Areas
Other Rett Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| NTI164 | Neurotech International | Phase 2 |
| RTT1 | Grann Pharmaceuticals | Pre-clinical |
| KIT-13 | NeuroCores | Pre-clinical |
| DPM-1003 | DepYmed | Phase 1 |
| ExoEdit® for Rett Syndrome | Evox Therapeutics | Pre-clinical |
| RVL-001 (vorinostat) | Unravel Biosciences | Clinical Trial Initiated |
| Rett Syndrome Program | Herophilus | Discovery |
| Glutamate Modulator for Rett Syndrome | Numedicus | Licensed/Orphan Designation |
| TTI-0102 | Thiogenesis Therapeutics | Phase 1 |
| DAYBUE® (trofinetide) | Neuren Pharmaceuticals | Approved |
| TSHA-102 | Taysha Gene Therapies | Phase 1/2 |
| Sarizotan | Newron Pharmaceuticals | Phase III |